{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:50:10Z","timestamp":1780631410768,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inactivating genomic alterations (GA) of the FANCC gene are associated with genomic instability, DNA cross-linking, and homologous DNA repair deficiency. Here, we evaluated the incidence of FANCC GA in renal tumors (RT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 463\u2009546 clinically advanced cancer (CAC) cases underwent hybrid capture-based comprehensive genomic profiling using the FDA-approved F1CDx assay to detect all classes of GA. Microsatellite instability (MSI) status, tumor mutational burden (TMB), genomic loss of heterozygosity, prediction of germline status, and genomic signature were determined with algorithm-based analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinically advanced cancers (0.43% of 1993) featured FANCC GA; 27 of these FANCC-mutated tumors (20 males, mean age 57) were RT (0.35% of 7668 RT). The primary tumor was sequenced in 9 cases and a metastatic site in 18 (5 lymph nodes, 4 soft tissues, 3 brains, 2 livers, 1 each lung, adrenal, eye, bone). Only 1 of 25 tested FANCC-mutated RT was MSI-high; 4 cases (15%) featured TMB \u226510 mutations\/Mb. The genomic signature could be assessed in 5 cases: 4 were MMR-deficient. The FANCC mutations included inactivating short variant mutations in 24 cases (10 nonsense, 10 frameshift, 2 non-frame, and 2 splice-site mutations) and 3 truncating rearrangements (FANCC: SUSD3, FANCC: FANCC, and FANCC: C20orf24). Interestingly, 14 (52%) of the FANCC-mutated RT were predicted to be germline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Somatic and germline mutations in FANCC occur in an exceedingly small subset of clinically advanced RT but at a similar rate to other cancers, and the genomic landscape does not appear to be different from RT with wild-type FANCC. Germline testing is warranted, as we see a high frequency of germline FANCC mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient Summary<\/jats:title>\n                    <jats:p>Our study highlights the rate of FANCC mutation in kidney cancer, which may be a therapeutic target and awaits further assessment and drug development. Also, it shows that FANCC mutations are more germline, requiring further genetic testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag012","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:37:42Z","timestamp":1768567062000},"source":"Crossref","is-referenced-by-count":1,"title":["Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4487-6293","authenticated-orcid":false,"given":"Devashish","family":"Desai","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Hematology and Medical Oncology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A","family":"Sager","sequence":"additional","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Basin","sequence":"additional","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Joan","family":"Morris","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Hematology and Medical Oncology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E","family":"Spiess","sequence":"additional","affiliation":[{"name":"Department of Urology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Warren Alpert Medical School of Brown University , Providence, RI,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M","family":"Kamat","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houton, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of Washington, Fred Hutchinson Cancer Center , Seattle, WA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mollapour","sequence":"additional","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Lin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]},{"name":"Foundation Medicine, Inc , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Basnet","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Hematology and Medical Oncology, SUNY Upstate Medical University , Syracuse, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Daneshvar","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Irvine Health , Orange, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026021302361879800_oyag012-B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.blre.2016.10.002","article-title":"Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia","volume":"31","author":"Mamrak","year":"2017","journal-title":"Blood Rev"},{"key":"2026021302361879800_oyag012-B2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fcell.2020.00160","article-title":"Fanconi anemia pathway: mechanisms of breast cancer predisposition development and potential therapeutic targets","volume":"8","author":"Fang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026021302361879800_oyag012-B3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/cancers12040829","article-title":"Exploring the role of mutations in Fanconi anemia genes in hereditary cancer patients","volume":"12","author":"Del Valle","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026021302361879800_oyag012-B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s42764-021-00043-0","article-title":"Fanconi anemia pathway and its relationship with cancer","volume":"2","author":"Dan","year":"2021","journal-title":"Genome Instab Dis"},{"key":"2026021302361879800_oyag012-B5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1476-4598-9-127","article-title":"Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents","volume":"9","author":"Palagyi","year":"2010","journal-title":"Mol Cancer"},{"key":"2026021302361879800_oyag012-B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40246-015-0054-y","article-title":"Update of the human and mouse Fanconi anemia genes","volume":"9","author":"Dong","year":"2015","journal-title":"Hum Genomics"},{"key":"2026021302361879800_oyag012-B7","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/ejhg.2016.44","article-title":"The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer","volume":"24","author":"Esteban-Jurado","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"2026021302361879800_oyag012-B8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/0008-5472.383.65.2","article-title":"Germ line Fanconi anemia complementation group C mutations and pancreatic cancer","volume":"65","author":"Couch","year":"2005","journal-title":"Cancer Res"},{"key":"2026021302361879800_oyag012-B9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0002-9440(10)63329-9","article-title":"Functional defects in the Fanconi anemia pathway in pancreatic cancer cells","volume":"165","author":"Heijden van der","year":"2004","journal-title":"Am J Pathol"},{"key":"2026021302361879800_oyag012-B10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-21-2096","article-title":"Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-heterozygosity score","volume":"28","author":"Westphalen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026021302361879800_oyag012-B11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/NBT.2696","article-title":"Development and validation of a clinical cancer genomic profilingtest based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2026021302361879800_oyag012-B12","doi-asserted-by":"publisher","first-page":"e1005965","DOI":"10.1371\/JOURNAL.PCBI.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"2026021302361879800_oyag012-B13","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/NAR\/GKU1075","article-title":"COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026021302361879800_oyag012-B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/S13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2026021302361879800_oyag012-B15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/J.JTHO.2019.12.107","article-title":"PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee","volume":"15","author":"Lantuejoul","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026021302361879800_oyag012-B16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s1097-2765(01)00173-3","article-title":"Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway","volume":"7","author":"Garcia-Higuera","year":"2001","journal-title":"Mol Cell"},{"key":"2026021302361879800_oyag012-B17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1241","article-title":"A novel ubiquitin ligase is deficient in Fanconi anemia","volume":"35","author":"Meetei","year":"2003","journal-title":"Nat Genet"},{"key":"2026021302361879800_oyag012-B18","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1093\/emboj\/cdf355","article-title":"FANCE: the link between Fanconi anaemia complex assembly and activity","volume":"21","author":"Pace","year":"2002","journal-title":"Embo J"},{"key":"2026021302361879800_oyag012-B19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12032-021-01507-9","article-title":"PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer","volume":"38","author":"Desai","year":"2021","journal-title":"Med Oncol"},{"key":"2026021302361879800_oyag012-B20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2026021302361879800_oyag012-B21","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"2026021302361879800_oyag012-B22","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026021302361879800_oyag012-B23","doi-asserted-by":"crossref","first-page":"26273","DOI":"10.1038\/srep26273","article-title":"Expression of an oncogenic BARD1 splice variant impairs homologous recombination and predicts response to PARP-1 inhibitor therapy in colon cancer","volume":"6","author":"Ozden","year":"2016","journal-title":"Sci Rep"},{"key":"2026021302361879800_oyag012-B24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann Oncol"},{"key":"2026021302361879800_oyag012-B25","doi-asserted-by":"publisher","first-page":"TPS1117","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS1117","article-title":"An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY","volume":"35","author":"Patsouris","year":"2017","journal-title":"JCO"},{"key":"2026021302361879800_oyag012-B26","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.1200\/JCO.2021.39.15_suppl.8562","article-title":"The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer","volume":"39","author":"Park","year":"2021","journal-title":"JCO"},{"key":"2026021302361879800_oyag012-B27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cllc.2021.01.001","article-title":"Phase 2 study of talazoparib in patients with homologous recombination repair-deficient squamous cell lung cancer: Lung-MAP substudy S1400G","volume":"22","author":"Owonikoko","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2026021302361879800_oyag012-B28","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.3802\/jgo.2021.32.e16","article-title":"Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer","volume":"32","author":"Okamoto","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"2026021302361879800_oyag012-B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.2018.36.5_suppl.48","article-title":"A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors","volume":"36","author":"Friedlander","year":"2018","journal-title":"JCO"},{"key":"2026021302361879800_oyag012-B30","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/2159-8290.CD-20-0163","article-title":"Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1\/2- and non\u2013BRCA1\/2-mutant cancers","volume":"10","author":"Yap","year":"2020","journal-title":"Cancer Discov"},{"key":"2026021302361879800_oyag012-B31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"2026021302361879800_oyag012-B32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-020-0301-x","article-title":"Genomic profiling in renal cell carcinoma","volume":"16","author":"Dizman","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2026021302361879800_oyag012-B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13578-020-00401-7","article-title":"Fanconi anemia pathway as a prospective target for cancer intervention","volume":"10","author":"Liu","year":"2020","journal-title":"Cell Biosci"},{"key":"2026021302361879800_oyag012-B34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1172\/JCI31245","article-title":"Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated","volume":"117","author":"Kennedy","year":"2007","journal-title":"J Clin Invest"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag012\/66483629\/oyag012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag012\/66483629\/oyag012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag012\/66483629\/oyag012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:36:26Z","timestamp":1770968186000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag012\/8431724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag012","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"oyag012"}}